|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02315 BIOCYTOGEN-B
Nominal 
60.950 -0.800 (-1.296%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 941,389 | 51.601% | 1,378,808 | 980,454 | 716,912 | 533,881 |
| Cost of Sales | (194,899) | 22.567% | (333,218) | (218,935) | (210,878) | (142,131) |
| Gross Profit | 746,490 | 61.596% | 1,045,590 | 761,519 | 506,034 | 391,750 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 41,572 | 99.904% | 63,689 | 14,195 | 4,879 | 3,923 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (20,501) | 72.917% | (22,306) | (29,753) | (10,027) | (14,770) | |
| Profit / (Loss) before Taxation | 248,569 | 316.922% | 188,030 | 42,940 | (380,156) | (601,353) | |
| Taxation | (7,475) | -35.677% | (14,831) | (9,403) | (2,796) | (804) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 1 | -- | 0 | 5 | 1 | 212 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 241,095 | 402.292% | 173,199 | 33,542 | (382,951) | (601,945) | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 33,415 | -0.450% | 66,730 | 85,780 | 89,686 | 53,972 |
| Depreciation & Amortisation | 81,660 | -4.041% | 160,458 | 169,181 | 189,982 | 174,099 |
| Directors' Emoluments | -- | -- | 15,776 | 8,422 | 6,331 | 3,672 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 54.000 | 350.000% | 43.000 | 8.000 | -96.000 | -158.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.925 | 0.531 | (0.192) | (0.796) |
| NBV per share ($) | 5.419 | -- | 4.867 | 2.088 | 1.968 | 2.870 |
| Remarks: | Real time quote last updated: 09/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 241,095 |
| %Change | 402.292% |
| EPS / (LPS) | RMB 0.540 |
| NBV Per Share (¥) | RMB 5.419 |